Guidelines for the diagnosis and management of asthma: a look at the key differences between BTS/SIGN and NICE

 
Research and Guideline updates
 
Guidelines for the diagnosis and management of asthma: a look at the key differences between BTS/SIGN and NICE
 FREE
 
John White1, James Y Paton2, Robert Niven3, Hilary Pinnock4 on behalf of the British Thoracic Society

The British Thoracic Society (BTS) first produced a guideline on asthma and its management in 1990. The first collaborative guideline with the Scottish Intercollegiate Guideline Network (SIGN) using evidence-based medicine methodology was published in 2003.1 It has since become a mainstay of asthma management across the UK and beyond with updates published regularly every 18–24 months. The latest BTS/SIGN guideline for the management of asthma was published in 2016.2 Both BTS and SIGN are committed to continuing updates with the next update planned for publication in 2019.

Following publication of National Institute for Health and Care Excellence (NICE) guidelines for diagnosis and monitoring, and for management of chronic asthma,3–5 there are now two if not three national guidelines, for England at least, with some (apparently) striking differences. This statement considers the similarities and differences to assist clinical colleagues in the care of people with asthma.

The evidence base considered by the BTS/SIGN and NICE guideline development groups is broadly the same for each guideline, but the methodology used to produce recommendations is significantly different:

  • SIGN methodology is a multidisciplinary clinically led process which employs robust critical appraisal of the literature, coupled with consideration of pragmatic studies to ensure that guidelines provide clinically relevant recommendations.

  • NICE methodology overlays critical appraisal of the literature with health economic modelling, with interpretation supported by advice from a multidisciplinary guideline development group.

These different processes have resulted in some discrepancies in recommendations made by BTS/SIGN and NICE. This article seeks to provide some context to these differences in key areas:

  • Diagnosis

  • Pharmacological management:

    • Treatment at diagnosis.

    • The introduction of leukotriene receptor antagonists (LTRA) after low-dose inhaled corticosteroids (ICS).

    • Maintenance and reliever therapy (MART).

    • Treatment beyond combined inhaler therapy.

    • Some other issues in managing asthma in children.

The BTS/SIGN guideline also provides recommendations for important aspects of asthma management that are not addressed within NICE guidelines. These include guidance on inhaler devices, the management of acute asthma attacks in both adults and children, the management of difficult asthma, guidance on asthma in adolescents, in pregnant women and on occupational factors.

FULL TEXT FREE

PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @BioMedCentral: World Allergy Organization Journal receives 70,000 accesses worldwide per month @worldallergy #openaccess https://t.co/I
4hreplyretweetfavorite
Interasma RT @BioMedCentral: Publish #openaccess in World Allergy Organization Journal, official journal of the @worldallergy https://t.co/d7VTeQ1AkF
4hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergy, Asthma & Immunology! https://t.co/G4dPzJldLA #londonmarathon
5hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/3TIxr4Dteg Thanks to @ThoraxBMJ @ACAAI @sergiobarbaecua #londonmarathon
5hreplyretweetfavorite
Interasma RT @worldallergy: April 22-28 is World Allergy Week 2018. Help increase awareness of Atopic Dermatitis/Eczema: An Itch that Rashes. There a…
5hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma